SCHEMBL276547

SCHEMBL276547

CC(=O)c1csc(-c2cccc(Cl)c2)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.46
PTGS2 P35354 1/20 0.46
ABL1 P00519 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
POLB P06746 1/20 0.45
KMT2A Q03164 2/20 0.44
BRD4 O60885 1/20 0.43
MAOB P27338 2/20 0.42
MAOA P21397 1/20 0.42
ESR2 Q92731 1/20 0.40
RORB Q92753 3/20 0.39
KDM1A O60341 1/20 0.39
ALOX5 P09917 1/20 0.39
RORC P51449 1/20 0.38
MAPT P10636 2/20 0.38
HPGD P15428 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14395501 0.85 BRD4 (0.40) PTPN1PTGS2ABL1SMN1; SMN2NPC1
SCHEMBL27849101 0.85 CHRNA7 (0.42) PTPN1PTGS2ABL1SMN1; SMN2NPC1
SCHEMBL16471130 0.84 AKR1C2 (0.43) SMN1; SMN2NPC1RAB9AMAPTHPGD
SCHEMBL14396014 0.83 BRD4 (0.38) PTPN1PTGS2ABL1SMN1; SMN2NPC1
SCHEMBL1783988 0.82 TRPM8 (0.47) SMN1; SMN2NPC1RAB9AKMT2AMAOB
SCHEMBL14395497 0.82 ATP4A (0.39) PTPN1PTGS2ABL1SMN1; SMN2NPC1
SCHEMBL277465 0.81 ABL1 (0.40) ABL1SMN1; SMN2NPC1RAB9APOLB
SCHEMBL280393 0.81 MAPT (0.53) PTPN1SMN1; SMN2NPC1RAB9APOLB
SCHEMBL277337 0.81 ABL1 (0.44) ABL1NPC1RAB9AKMT2ARORB
SCHEMBL1484281 0.79 ALDH1A1 (0.43) SMN1; SMN2KMT2ARORBRORCMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2246343-B1 PROCESS FOR PRODUCTION OF THIOPHENE COMPOUND AND INTERMEDIATE THEREOF NISSAN CHEMICAL IND LTD (JP) 2016-05-18 EP disclosed
US-20140051857-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2014-02-20 US disclosed
US-20140051857-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2014-02-20 US disclosed
US-8642786-B2 Process for producing thiophene compound and intermediate thereof NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2014-02-04 US disclosed
US-8642786-B2 Process for producing thiophene compound and intermediate thereof NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2014-02-04 US disclosed
US-8642786-B2 Process for producing thiophene compound and intermediate thereof NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2014-02-04 US disclosed
US-20140005413-A2 PROCESS FOR PRODUCING THIOPHENE COMPOUND AND INTERMEDIATE THEREOF NISSAN CHEMICAL IND LTD (JP) 2014-01-02 US disclosed
US-8552031-B2 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-10-08 US disclosed
US-20130204013-A1 PROCESS FOR PRODUCING THIOPHENE COMPOUND AND INTERMEDIATE THEREOF NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-08-08 US disclosed
US-20130204013-A1 PROCESS FOR PRODUCING THIOPHENE COMPOUND AND INTERMEDIATE THEREOF NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-08-08 US disclosed
US-7576115-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-08-18 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-7351841-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-04-01 US disclosed
US-7351841-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-04-01 US disclosed
US-20080027068-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2008-01-31 US disclosed
US-20080027068-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2008-01-31 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130204013-A1 PROCESS FOR PRODUCING THIOPHENE COMPOUND AND INTERMEDIATE THEREOF TST, SULT1E1, GRHPR PTPN1 2511/4885PTGS2 749/4885ABL1 2389/4885
US-20080027068-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 PTPN1 1463/4885PTGS2 1737/4885ABL1 797/4885
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL PTPN1 1638/4885PTGS2 1297/4885ABL1 1044/4885
US-20140051857-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 PTPN1 1416/4885PTGS2 1765/4885ABL1 758/4885
US-20140005413-A2 PROCESS FOR PRODUCING THIOPHENE COMPOUND AND INTERMEDIATE THEREOF TST, SULT1E1, GRHPR PTPN1 2511/4885PTGS2 749/4885ABL1 2389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.